Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. - Test2 - elhamkhani - TriplyDB

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

http://www.wikidata.org/entity/Q37657070

about

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis Cutaneous adverse events in multiple sclerosis patients treated with daclizumab Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis Emerging immunopharmacological targets in multiple sclerosis.Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.Daclizumab.

P2860

Q26775111-B177BA18-0E86-4CA5-A5D8-87DE91141B54 Q33589947-ECD55259-8447-4321-9C5C-1CC8CA4D90E5 Q36691970-5796BAE2-CC31-46D4-93DE-A7289F4E80A6 Q37080630-7773603E-FC42-4EAF-9493-46C7C895FB2D Q37559970-3D7684FB-9745-4F6F-BD5C-A7C60D931BF2 Q38218692-9ED55710-FA38-4BC4-ACB2-1064B06F61D4 Q38397484-E9BE49E9-6FE2-4768-B3AE-0EA250EC4106 Q39434495-BFA762ED-3558-441E-9E8F-E8C9FDAEFF95 Q46487963-B88FB51E-D433-450F-B001-4C4B4BAC329B

P2860

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

http://www.wikidata.org/entity/Q37657070

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

@en

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

@nl

type

label

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

@en

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

@nl

prefLabel

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

@en

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

@nl

P1433

Q37657070-AE5111F2-3F2E-4C82-9D07-C0F74E19FA48

P1476

Q37657070-40A8173D-59D2-47CF-817B-9F0241C0E782

P2093

Q37657070-2D29C4D4-7194-42A7-851E-0F17BA7F54C9

Q37657070-6D06D6C7-B177-4253-8A03-57FEF2FD8D95

Q37657070-A366F2C1-D3B3-4DC1-A0E9-C8067A0EFB2D

Q37657070-B45BCBF9-7D74-491F-88AF-9ED57CF97C09

Q37657070-DDB3C8F6-36EC-4D59-BC88-3CAE7C17D0C7

Q37657070-F5B3DE19-B054-4ABF-913C-1305C75E2DD5

P2860

Q37657070-379C344A-E56B-4E5F-BEAE-F2184FE5485B

Q37657070-4AD32341-9467-4343-B250-802F703EBA75

Q37657070-565A0A85-656C-4B60-A1E0-035B17E376EE

Q37657070-820DC835-998A-420F-AB11-65B7A6B19AFC

Q37657070-959D09C8-007F-4F6B-92BC-64CF2408EC4F

Q37657070-A4A5C09B-3B18-408E-99A2-B46575E15F63

Q37657070-B5C82CBB-ADD5-4C54-8691-628E7FBF87DF

Q37657070-C03995FB-B100-42F2-BFC1-5A0CEBA6D5FC

Q37657070-F011F89E-EC1C-4356-A047-1545EB621805

P304

Q37657070-809833B3-283F-44E5-AE3B-D383467B7B94

P31

Q37657070-CFC7044E-7285-494B-910F-54436DE57F93

P356

Q37657070-19E8876E-F497-4962-AB51-84F6146A82ED

P407

Q37657070-DA5C7F5C-EE65-403F-B5AF-5CB2A647CE50

P433

Q37657070-B3F8E217-3DB1-4DE6-8419-EFE0E42E9F26

P478

Q37657070-165D1B10-EBF3-48C0-8403-71B7C9A40E76

P50

Q37657070-F48A550C-FBDC-49E1-95BB-DB35EC2D8B10

P577

Q37657070-75D947E6-9801-4A69-8AE6-8E782F843770

P698

Q37657070-F77A3591-B09F-4F50-855C-AD99419C3075

P921

Q37657070-1FEE19D2-C24F-47CF-BAE1-9EC42C97656F

P932

Q37657070-45C34C54-166D-4F5D-AEB2-FF4F471B3467

P356

WNL.0000000000000222

P1433

P1476

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.

@en

P2093

Bibiana Bielekova

http://www.w3.org/2001/XMLSchema#string

Irene Cortese

http://www.w3.org/2001/XMLSchema#string

Jiwon Oh

http://www.w3.org/2001/XMLSchema#string

Joan Ohayon

http://www.w3.org/2001/XMLSchema#string

Scott D Newsome

http://www.w3.org/2001/XMLSchema#string

Shiv Saidha

http://www.w3.org/2001/XMLSchema#string

P2860

Daclizumab therapy for multiple sclerosis

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Monoclonal antibodies in MS: mechanisms of action.

An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.

Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.

A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

P304

984-988

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000000222

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Peter A Calabresi

P577

2014-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24532277

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3963003

http://www.w3.org/2001/XMLSchema#string